Share Price and Basic Stock Data
Last Updated: January 23, 2026, 6:18 pm
| PEG Ratio | -1.50 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dr Lalchandani Labs Ltd operates within the Hospitals & Medical Services sector, with its share price currently at ₹21.4 and a market capitalization of ₹9.26 Cr. The company reported sales of ₹4.81 Cr for the fiscal year ending March 2024, a decline from ₹5.04 Cr in the previous year. This downward trend in sales is evident in the quarterly data, with the most recent figures showing ₹2.73 Cr in sales for September 2023, compared to ₹7.07 Cr in March 2021. The company has seen fluctuations in revenue, peaking at ₹11.28 Cr in March 2022 but subsequently declining. The operating profit margin (OPM) was reported at 12.68% for the current fiscal year, indicating a recovery from negative margins witnessed in previous periods. The company’s ability to stabilize sales and improve margins will be critical as it navigates an evolving healthcare landscape.
Profitability and Efficiency Metrics
Profitability metrics for Dr Lalchandani Labs reflect significant volatility. The net profit for the fiscal year ending March 2024 was ₹0.62 Cr, a recovery from a net loss of ₹1.56 Cr in the prior year. The earnings per share (EPS) stood at ₹0.96 for March 2025, an improvement compared to the negative EPS of ₹-3.61 reported in March 2023. However, the return on equity (ROE) is relatively low at 3.08%, indicating that the company is not effectively utilizing its equity base to generate profits. The interest coverage ratio (ICR) reported at 10.90x provides a buffer against financial distress, suggesting manageable debt levels and a capacity to cover interest obligations. Despite the challenges, the operating profit margin of 12.68% signifies that the company is beginning to control its operational costs more effectively.
Balance Sheet Strength and Financial Ratios
Dr Lalchandani Labs maintains a cautious balance sheet, with total borrowings reported at ₹4.58 Cr against reserves of ₹5.82 Cr. The debt-to-equity ratio stands at 0.40, indicating a moderate level of leverage. The company has consistently maintained a current ratio above 1, currently reported at 1.92, which suggests it can cover its short-term liabilities with its current assets. However, the cash conversion cycle (CCC) is notably high at 556.91 days, indicating inefficiencies in managing receivables and inventory. The price-to-book value (P/BV) ratio is low at 0.44x, suggesting that the stock is undervalued relative to its book value, which could attract value-focused investors. The efficiency ratios indicate that while the company has room for improvement, it also possesses a solid foundation of assets relative to liabilities.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dr Lalchandani Labs indicates a significant shift in ownership structure. As of September 2025, promoters hold 31.15% of the shares, a sharp decline from 60.78% in March 2020. This reduction could signal a lack of confidence from the promoters or a strategic divestment to enhance liquidity. Conversely, public ownership has increased to 68.84%, suggesting growing interest from retail investors. The number of shareholders has surged to 206, up from 165 in March 2024, reflecting enhanced investor participation. This increasing public stake may bolster market confidence, yet the declining promoter share could raise concerns about long-term strategic direction. The shift in shareholding dynamics will be crucial in understanding future governance and operational strategies.
Outlook, Risks, and Final Insight
Looking ahead, Dr Lalchandani Labs faces both opportunities and challenges. The company’s recovery in profitability and operating margins suggests potential for growth, especially if it can stabilize sales and improve operational efficiencies. However, risks remain, including a high cash conversion cycle that may hinder cash flow and operational agility, and a low ROE, which raises concerns about capital utilization. The significant drop in promoter stake could also lead to uncertainty regarding management’s commitment. In a scenario where the company successfully addresses these operational inefficiencies and enhances its market presence, it could see renewed investor confidence and a potential rebound in share price. Conversely, failure to improve financial metrics could lead to continued volatility and diminished market interest.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 9.05 Cr. | 20.9 | 28.7/9.80 | 19.3 | 23.4 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 327 Cr. | 166 | 221/72.9 | 23.3 | 45.2 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 35,703 Cr. | 1,747 | 2,372/1,259 | 42.0 | 199 | 0.26 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 255 Cr. | 122 | 141/55.0 | 380 | 29.2 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 12,095.00 Cr | 513.98 | 116.15 | 74.20 | 0.07% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.03 | 3.07 | 2.71 | 7.07 | 8.02 | 3.26 | 2.28 | 2.76 | 2.73 | 2.08 | 2.13 | 2.33 | 2.05 |
| Expenses | 2.30 | 2.53 | 2.14 | 5.40 | 6.07 | 2.81 | 2.46 | 2.50 | 2.38 | 1.04 | 1.59 | 1.82 | 1.79 |
| Operating Profit | 0.73 | 0.54 | 0.57 | 1.67 | 1.95 | 0.45 | -0.18 | 0.26 | 0.35 | 1.04 | 0.54 | 0.51 | 0.26 |
| OPM % | 24.09% | 17.59% | 21.03% | 23.62% | 24.31% | 13.80% | -7.89% | 9.42% | 12.82% | 50.00% | 25.35% | 21.89% | 12.68% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.24 | 0.00 | 0.00 | 0.29 |
| Interest | 0.09 | 0.09 | 0.05 | 0.30 | 0.24 | 0.33 | 0.48 | 0.51 | 0.11 | 0.28 | 0.05 | 0.03 | 0.01 |
| Depreciation | 0.21 | 0.22 | 0.23 | 0.29 | 0.28 | 0.30 | 0.33 | 0.34 | 0.33 | 0.29 | 0.28 | 0.28 | 0.28 |
| Profit before tax | 0.43 | 0.23 | 0.29 | 1.08 | 1.43 | -0.18 | -0.98 | -0.59 | -0.09 | 0.71 | 0.21 | 0.20 | 0.26 |
| Tax % | 0.00% | 82.61% | 24.14% | 27.78% | 25.17% | -22.22% | 0.00% | 0.00% | 0.00% | 0.00% | 23.81% | -35.00% | 26.92% |
| Net Profit | 0.43 | 0.04 | 0.23 | 0.79 | 1.07 | -0.13 | -0.97 | -0.59 | -0.09 | 0.71 | 0.15 | 0.27 | 0.20 |
| EPS in Rs | 0.99 | 0.09 | 0.53 | 1.82 | 2.47 | -0.30 | -2.24 | -1.36 | -0.21 | 1.64 | 0.35 | 0.62 | 0.46 |
Last Updated: December 27, 2025, 5:35 am
Below is a detailed analysis of the quarterly data for Dr Lalchandani Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2.05 Cr.. The value appears to be declining and may need further review. It has decreased from 2.33 Cr. (Mar 2025) to 2.05 Cr., marking a decrease of 0.28 Cr..
- For Expenses, as of Sep 2025, the value is 1.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.82 Cr. (Mar 2025) to 1.79 Cr., marking a decrease of 0.03 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.26 Cr.. The value appears to be declining and may need further review. It has decreased from 0.51 Cr. (Mar 2025) to 0.26 Cr., marking a decrease of 0.25 Cr..
- For OPM %, as of Sep 2025, the value is 12.68%. The value appears to be declining and may need further review. It has decreased from 21.89% (Mar 2025) to 12.68%, marking a decrease of 9.21%.
- For Other Income, as of Sep 2025, the value is 0.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.29 Cr., marking an increase of 0.29 Cr..
- For Interest, as of Sep 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.03 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.28 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.28 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.20 Cr. (Mar 2025) to 0.26 Cr., marking an increase of 0.06 Cr..
- For Tax %, as of Sep 2025, the value is 26.92%. The value appears to be increasing, which may not be favorable. It has increased from -35.00% (Mar 2025) to 26.92%, marking an increase of 61.92%.
- For Net Profit, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.27 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.07 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.46. The value appears to be declining and may need further review. It has decreased from 0.62 (Mar 2025) to 0.46, marking a decrease of 0.16.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:50 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 | 4.38 |
| Expenses | 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.52 | 3.61 |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 0.93 | 0.77 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 20.90% | 17.58% |
| Other Income | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.13 | 0.29 |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 | 0.04 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 | 0.56 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 | 0.46 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | -2.44% | |
| Net Profit | 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 | 0.47 |
| EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 0.97 | 1.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 103.85% | -11.32% | 114.89% | -7.92% | -267.74% | 139.74% | -32.26% |
| Change in YoY Net Profit Growth (%) | 0.00% | -115.17% | 126.21% | -122.81% | -259.82% | 407.49% | -172.00% |
Dr Lalchandani Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -27% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -23% |
| TTM: | 155% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 0% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:46 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
| Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.62 | 5.82 |
| Borrowings | 1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 4.07 | 4.58 |
| Other Liabilities | 1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 1.72 | 1.36 |
| Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
| Fixed Assets | 2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.51 | 3.38 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 | 0.27 |
| Other Assets | 3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.96 | 12.44 |
| Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
Below is a detailed analysis of the balance sheet data for Dr Lalchandani Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.33 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.33 Cr..
- For Reserves, as of Sep 2025, the value is 5.82 Cr.. The value appears strong and on an upward trend. It has increased from 5.62 Cr. (Mar 2025) to 5.82 Cr., marking an increase of 0.20 Cr..
- For Borrowings, as of Sep 2025, the value is 4.58 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4.07 Cr. (Mar 2025) to 4.58 Cr., marking an increase of 0.51 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.36 Cr.. The value appears to be improving (decreasing). It has decreased from 1.72 Cr. (Mar 2025) to 1.36 Cr., marking a decrease of 0.36 Cr..
- For Total Liabilities, as of Sep 2025, the value is 16.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.74 Cr. (Mar 2025) to 16.09 Cr., marking an increase of 0.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.38 Cr.. The value appears to be declining and may need further review. It has decreased from 3.51 Cr. (Mar 2025) to 3.38 Cr., marking a decrease of 0.13 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.27 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.27 Cr..
- For Other Assets, as of Sep 2025, the value is 12.44 Cr.. The value appears strong and on an upward trend. It has increased from 11.96 Cr. (Mar 2025) to 12.44 Cr., marking an increase of 0.48 Cr..
- For Total Assets, as of Sep 2025, the value is 16.09 Cr.. The value appears strong and on an upward trend. It has increased from 15.74 Cr. (Mar 2025) to 16.09 Cr., marking an increase of 0.35 Cr..
Notably, the Reserves (5.82 Cr.) exceed the Borrowings (4.58 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.26 | 0.30 | -0.50 | -1.80 | -2.68 | -6.31 | -3.26 | -3.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 |
| Working Capital Days | 162.22 | 167.23 | 206.43 | 104.50 | 77.98 | 188.29 | 163.91 | 156.66 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 2.81% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| Diluted EPS (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| Cash EPS (Rs.) | 2.27 | 2.87 | -2.08 | 3.51 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.94 | 21.98 | 20.56 | 24.16 | 22.01 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.98 | 22.02 | 20.59 | 24.20 | 22.04 |
| Revenue From Operations / Share (Rs.) | 10.28 | 11.10 | 11.63 | 26.03 | 22.57 |
| PBDIT / Share (Rs.) | 2.15 | 1.00 | 0.20 | 5.55 | 5.12 |
| PBIT / Share (Rs.) | 0.84 | -0.43 | -1.33 | 4.20 | 3.93 |
| PBT / Share (Rs.) | 0.92 | 1.43 | -3.61 | 2.97 | 3.18 |
| Net Profit / Share (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| PBDIT Margin (%) | 20.89 | 9.04 | 1.75 | 21.33 | 22.68 |
| PBIT Margin (%) | 8.22 | -3.93 | -11.40 | 16.12 | 17.41 |
| PBT Margin (%) | 9.03 | 12.83 | -31.00 | 11.41 | 14.08 |
| Net Profit Margin (%) | 9.36 | 12.83 | -31.00 | 8.27 | 10.34 |
| Return on Networth / Equity (%) | 4.19 | 6.48 | -17.54 | 8.91 | 10.60 |
| Return on Capital Employeed (%) | 3.63 | -1.89 | -4.63 | 13.71 | 13.81 |
| Return On Assets (%) | 2.64 | 4.11 | -8.82 | 5.14 | 6.65 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.37 | 0.25 | 0.27 |
| Total Debt / Equity (X) | 0.40 | 0.35 | 0.52 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.28 | 0.29 | 0.28 | 0.67 | 0.72 |
| Current Ratio (X) | 1.92 | 1.88 | 2.07 | 2.22 | 2.98 |
| Quick Ratio (X) | 1.69 | 1.60 | 1.78 | 1.90 | 2.75 |
| Inventory Turnover Ratio (X) | 3.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 10.90 | 1.13 | 0.08 | 4.52 | 6.81 |
| Interest Coverage Ratio (Post Tax) (X) | 4.46 | -0.49 | -0.58 | 2.75 | 4.10 |
| Enterprise Value (Cr.) | 5.20 | 7.92 | 13.89 | 14.81 | 6.53 |
| EV / Net Operating Revenue (X) | 1.17 | 1.65 | 2.76 | 1.31 | 0.66 |
| EV / EBITDA (X) | 5.58 | 18.19 | 157.32 | 6.15 | 2.94 |
| MarketCap / Net Operating Revenue (X) | 0.99 | 1.42 | 2.44 | 1.27 | 0.61 |
| Price / BV (X) | 0.44 | 0.71 | 1.38 | 1.37 | 0.63 |
| Price / Net Operating Revenue (X) | 0.99 | 1.42 | 2.44 | 1.27 | 0.61 |
| EarningsYield | 0.09 | 0.09 | -0.12 | 0.06 | 0.16 |
After reviewing the key financial ratios for Dr Lalchandani Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.27. This value is below the healthy minimum of 3. It has decreased from 2.87 (Mar 24) to 2.27, marking a decrease of 0.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.94. It has increased from 21.98 (Mar 24) to 22.94, marking an increase of 0.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.98. It has increased from 22.02 (Mar 24) to 22.98, marking an increase of 0.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.28. It has decreased from 11.10 (Mar 24) to 10.28, marking a decrease of 0.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.00 (Mar 24) to 2.15, marking an increase of 1.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.84. This value is within the healthy range. It has increased from -0.43 (Mar 24) to 0.84, marking an increase of 1.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.92. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 0.92, marking a decrease of 0.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 2. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For PBDIT Margin (%), as of Mar 25, the value is 20.89. This value is within the healthy range. It has increased from 9.04 (Mar 24) to 20.89, marking an increase of 11.85.
- For PBIT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has increased from -3.93 (Mar 24) to 8.22, marking an increase of 12.15.
- For PBT Margin (%), as of Mar 25, the value is 9.03. This value is below the healthy minimum of 10. It has decreased from 12.83 (Mar 24) to 9.03, marking a decrease of 3.80.
- For Net Profit Margin (%), as of Mar 25, the value is 9.36. This value is within the healthy range. It has decreased from 12.83 (Mar 24) to 9.36, marking a decrease of 3.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.19. This value is below the healthy minimum of 15. It has decreased from 6.48 (Mar 24) to 4.19, marking a decrease of 2.29.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.63. This value is below the healthy minimum of 10. It has increased from -1.89 (Mar 24) to 3.63, marking an increase of 5.52.
- For Return On Assets (%), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 4.11 (Mar 24) to 2.64, marking a decrease of 1.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.40, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.28. It has decreased from 0.29 (Mar 24) to 0.28, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 1.92, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.69, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.26. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.26, marking an increase of 3.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.90. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 10.90, marking an increase of 9.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.46. This value is within the healthy range. It has increased from -0.49 (Mar 24) to 4.46, marking an increase of 4.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5.20. It has decreased from 7.92 (Mar 24) to 5.20, marking a decrease of 2.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.17. This value is within the healthy range. It has decreased from 1.65 (Mar 24) to 1.17, marking a decrease of 0.48.
- For EV / EBITDA (X), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 18.19 (Mar 24) to 5.58, marking a decrease of 12.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.42 (Mar 24) to 0.99, marking a decrease of 0.43.
- For Price / BV (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 24) to 0.44, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.42 (Mar 24) to 0.99, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.09.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lalchandani Labs Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.63% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.19% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.3 (Industry average Stock P/E: 116.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.4
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | M-20, Basement, Greater Kailash, New Delhi Delhi 110048 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Arjan Lal Chandani | Chairman & Managing Director |
| Mr. Mohit Lal Chandani | WholeTime Director & CEO |
| Mrs. Anchal Gupta | Executive Director & CFO |
| Mrs. Swati Chandra | Non Executive Director |
| Mr. Rajiv Handa | Independent Director |
| Mr. Mohan Lal Gandhi | Independent Director |
FAQ
What is the intrinsic value of Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd's intrinsic value (as of 23 January 2026) is ₹9.89 which is 52.68% lower the current market price of ₹20.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9.05 Cr. market cap, FY2025-2026 high/low of ₹28.7/9.80, reserves of ₹5.82 Cr, and liabilities of ₹16.09 Cr.
What is the Market Cap of Dr Lalchandani Labs Ltd?
The Market Cap of Dr Lalchandani Labs Ltd is 9.05 Cr..
What is the current Stock Price of Dr Lalchandani Labs Ltd as on 23 January 2026?
The current stock price of Dr Lalchandani Labs Ltd as on 23 January 2026 is ₹20.9.
What is the High / Low of Dr Lalchandani Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dr Lalchandani Labs Ltd stocks is ₹28.7/9.80.
What is the Stock P/E of Dr Lalchandani Labs Ltd?
The Stock P/E of Dr Lalchandani Labs Ltd is 19.3.
What is the Book Value of Dr Lalchandani Labs Ltd?
The Book Value of Dr Lalchandani Labs Ltd is 23.4.
What is the Dividend Yield of Dr Lalchandani Labs Ltd?
The Dividend Yield of Dr Lalchandani Labs Ltd is 0.00 %.
What is the ROCE of Dr Lalchandani Labs Ltd?
The ROCE of Dr Lalchandani Labs Ltd is 2.81 %.
What is the ROE of Dr Lalchandani Labs Ltd?
The ROE of Dr Lalchandani Labs Ltd is 3.08 %.
What is the Face Value of Dr Lalchandani Labs Ltd?
The Face Value of Dr Lalchandani Labs Ltd is 10.0.